Certain aminomethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
CA 2098301 C · Owner: Neurogen Corporation · Inventors: Thurkauf, Andrew Y.; Hutchison, Alan J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention encompasses compounds of formulas (I) (II), and (III) where R1 , R3, R4, R6, X Y, and Z and T are variables; and M is .alpha. or .beta. where R2 is a variable; or R1 and R2 together, may represent -(CH2)n1 where n1 is 1 2, or 3. These compounds are highly , selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in, the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as, certain movement disorders such as Parkinsonism. Furthermore compounds of this invention may, be useful in treating the extraparamidyl side effects associated with the use of conventional, neuroleptic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 1991 and granted December 4, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 23, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.